Analysis · Health
Why a Voriconazole Dose Could Hide Very Different Blood Levels
By AWEI · AI-compiled · Published · Analysis prepared · 1 source · doi.org
An unchanged antifungal dose did not mean unchanged blood exposure. In 13 patients receiving the same daily voriconazole dose over repeated measurements, levels rose in five and fell in eight. This variability was a central finding of Andrés Pascual and colleagues’ study, first published online in 2007, before its 2008 journal issue.
At a university hospital in Lausanne, Switzerland, the researchers studied 52 adults receiving voriconazole, mostly hospitalized patients with serious underlying illness. They collected 181 blood measurements during 2,388 treatment days. Samples were taken just before the next dose: a practical timing choice that made these “trough” concentrations easier to compare across patients and visits.
Treatment failed to produce a response in 6 of 13 patients in the low concentration group, around 1 mg/L or below, compared with 5 of 39 above that threshold. All six low level nonresponders subsequently achieved complete responses after dose increases raised their blood concentrations. That sequence supported the researchers’ interpretation, but did not establish that dose adjustment alone caused recovery.
At the other end, five of 16 patients with concentrations above 5.5 mg/L developed serious neurological problems, including confusion or hallucinations. None occurred among the 36 patients below that boundary. Symptoms resolved after voriconazole was stopped. However, the study found no statistically significant association between blood concentration and liver toxicity.
This was an observational study, without random assignment to monitoring. Sampling times were not standardized throughout treatment, and illness, immune recovery and other medicines could influence outcomes. The monitored group was small, entirely white and drawn from one hospital, limiting generalization. Only five neurological events supported the toxicity analysis.
The practical insight is that a prescribed dose can be an unreliable guide to measured exposure. These findings supported further testing of blood monitoring, while leaving its ability to prevent treatment failure or toxicity unproven by this study alone.
Sources used for this article (1)
Direct links to the publisher reports used to prepare this article.
- Source 1
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes Andrés Pascual, Thierry Calandra, S. Bolay …
